Research programme: nitric oxide synthase gene therapy - Cardion/Boehringer Ingelheim

Drug Profile

Research programme: nitric oxide synthase gene therapy - Cardion/Boehringer Ingelheim

Latest Information Update: 02 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 14 Jun 2001 New profile
  • 14 Jun 2001 Preclinical development for Vascular disorders in Austria (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top